Long-term results and prognostic analysis in advanced and recurrent/refractory epithelial ovarian cancer treated by high-dose cyclophosphamide, adriamycin, and cisplatin with autologous bone marrow transplantation
Long-term results and prognostic analysis in advanced and recurrent/refractory epithelial ovarian cancer treated by high-dose cyclophosphamide, adriamycin, and cisplatin with autologous bone marrow transplantation
复制标题
大剂量环磷酰胺、阿霉素和顺铂联合自体骨髓移植治疗晚期和复发/难治性上皮性卵巢癌的长期结果和预后分析
DOI：
--
复制
发表时间：
1999
影响因子：
3.3
通讯作者：
M. Yasuda
中科院分区：
文献类型：
--
作者：
T. Shinozuka;T. Muramatsu;T. Miyamoto;T. Hirasawa;M. Murakami;T. Makino;S. Sadahiro;Y. Tanaka;M. Yasuda
AbstractBackground。对晚期或复发/难治性（r/r）上皮性卵巢癌患者进行高剂量化疗（HDC）联合自体骨髓移植（ABMT）的远期疗效和预后分析进行评估。
AbstractBackground. The efficacy of high-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) was evaluated in patients with advanced or recurrent/refractory (r/r) epithelial ovarian cancer in terms of long-term results and prognostic analysis.
Methods. Between 1984 and 1991, 47 patients were prescribed two courses of HDC, consisting of cyclophosphamide (1600–2400 mg/m2), adriamycin (80–100 mg/m2), and cisplatin (100–150 mg/m2) after maximal cytoreductive surgery. Prior to HDC, platinum-based chemotherapy was administered for optimal cytoreduction.
Results. The 5- and 8-year overall survival (OS) rates (%) of the 47 patients were 44.7% and 40.4%, and the 5- and 8-year disease-free survival (DFS) rates (%) were 29.8% and 27.7%, respectively. The 5- and 8-year OS rates (%) by stage were: stage III, 60.0% and 52.0%; stage IV, 33.3% and 33.3%; and r/r, 20.0% and 20.0%. The 5- and 8-year DFS rates (%) by stage were: stage III, 40.0% and 36.0%; stage IV, 25.0% and 25.0%; and r/r, 10.0% and 10.0%, respectively. Significantly better long-term survival (P < 0.01) was obtained in the group with no residual disease or residual disease <0.5 cm than in the groups with residual disease of 0.5–2 cm and >2 cm. In the 32 stage III/IV patients, the group given two courses of 150 mg/m2 cisplatin (n = 18) showed significantly better long-term survival (P < 0.05) than another group given two courses of 100 or 120 mg/m2 cisplatin (n = 14).
Conclusions. Administration of two courses of HDC con-taining 2400 mg/m2 cyclophosphamide, 100 mg/m2 adriamycin, and 150 mg/m2 cisplatin per course followed by ABMT appears to be a promising procedure for achieving long-term survival in patients with chemosensitive advanced or r/r epithelial ovarian cancers with no or minimal residual disease.
使用外周血祖细胞和非格司亭进行基于卡铂的化疗的同时剂量递增和时间表强化：一项 I 期试验。
影响因子：
11.2
作者：
Fennelly,D;Wasserheit,C;Schneider,J;Hakes,T;Reich,L;Curtin,J;Yao,TJ;Markman,M;Norton,L;Crown,J
通讯作者：
Crown,J
使用外周血祖细胞支持对晚期卵巢癌患者进行紫杉醇和高剂量卡铂的剂量递增。
DOI：
--
发表时间：
1997
期刊：
Seminars in oncology.
影响因子：
--
作者：
Fennelly,DW;Aghajanian,C;Shapiro,F;O'Flaherty,C;O'Connor,K;Curtin,JP;Crown,JP;Hoskins,WJ;Spriggs,DR
通讯作者：
Spriggs,DR